New Era For Schizophrenia Therapy Beckons As Karuna Soars On Promising Phase III Data
Mechanism Exceeds Efficacy Expectations
Executive Summary
The PureTech Health-founded entity believes it has made a significant step forward in the treatment of schizophrenia with its muscarinic-receptor acting agent KarXT, which could offer a completely new way to address all three symptom domains of the disease.
You may also be interested in...
PureTech Cashes In On Promise Of Karuna Schizophrenia Drug
Karuna’s KarXT could be the first new mechanism for treating schizophrenia approved in more than 50 years and founder PureTech is tapping into that promise by linking up with Royalty Pharma and boosting its cashpile.
Karuna Gears Up To File KarXT, A Schizophrenia ‘Gamechanger’
New CEO Bill Meury said Karuna had plenty of time, money and physician enthusiasm to ensure a US launch in 2024 would be a success.
Biopharma Funding Contracted Last Year – And 2023 Will See The Squeeze Continue
Now the pandemic-era biotech boom is over, biopharma companies and investors are both adjusting their financing strategies to survive and even thrive in the new environment.